Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 31Cyclophosphamide 27Mycophenolic Acid 22Whole-Body Irradiation 21Tacrolimus 21ruxolitinib 19Peripheral Blood Stem Cell Transplantation 19Busulfan 19Antilymphocyte Serum 16fludarabine 14Melphalan 12Methotrexate 11Cyclosporine 10thymoglobulin 9Cord Blood Stem Cell Transplantation 7Sirolimus 6Radiotherapy 6Etoposide 6Azacitidine 6Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclosporins 4pomalidomide 3parsaclisib 3Surveys and Questionnaires 3Rituximab 3Prednisone 3Filgrastim 3Cytarabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Primary Myelofibrosis × INCB059872 × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡